VeinWay Ltd.

VeinWay Ltd. is a medical device company founded in 2020 by Jordan Pollack within the MEDX Xelerator incubator. The company's slogan "Changing the paradigm on treating chronic venous disease" reflects its mission to address unmet needs in the treatment of Chronic Venous Occlusions (CVOs). VeinWay's Traversa is the first dedicated device designed for venous recanalization, aiming to improve outcomes and enable physicians to reliably, safely, and easily complete endovascular procedures for the effective treatment of CVOs. The innovation has a significantly different approach compared to existing solutions on the market or currently in development, positioning it as a disruptive technology in the Health Care and Medical Devices industries. The company conducted discussions with established physicians from Europe, Israel, and the US, revealing the high unmet need for crossing CVOs in interventional radiology. With failure rates estimated between 10%-17%, and only around 10-13% of patients who need a venous stent actually receive one, VeinWay's Traversa aims to democratize physician access to the treatment of CVOs. The technology provides an unparalleled level of control that will enable interventional radiologists and vascular surgeons to cross occlusions every time, addressing the challenges posed by cumbersome recanalization of chronically occluded veins. The last Series A investment at 08 September 2023 reflects the interest and confidence of investors in VeinWay's innovative solution for the treatment of CVOs. As the company continues to progress, its ability to disrupt the market and improve patient outcomes could make it an attractive prospect for further investment. Based in Israel, VeinWay Ltd. stands at the forefront of addressing critical unmet needs in the field of interventional radiology and vascular surgery with its groundbreaking Traversa technology.